Search research articles
Contact Us
Filters
Showing results (11-20 of 59) with videos related to
Page
of 6
Sort By:
American Journal of Clinical Oncology
|
January 31, 2015
Cancer Survivorship and Models of Survivorship Care: A Review
Kenneth D Miller, Manjari Pandey, Rohit Jain, et al.
Current Oncology (Toronto, Ont.)
|
February 24, 2023
Real-World Molecular Biomarker Testing Patterns and Results for Advanced Gastroesophageal Cancers in the United States
Rutika Mehta, Astra M Liepa, Shen Zheng, et al.
Expert Opinion on Investigational Drugs
|
March 4, 2021
Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies
Rutika Mehta, Anthony C Wood, James Yu, et al.
Journal of Clinical Pathology
|
August 13, 2010
Expression of high-molecular-weight cytokeratin (34betaE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast
Rutika Mehta, Rohit K Jain, Nour Sneige, et al.
Oncology Reports
|
September 30, 2010
Loss of ERα and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model
Kasi McCune, Rutika Mehta, Mangesh A Thorat, et al.
American Journal of Clinical Oncology
|
September 12, 2015
Patterns of Long-term Cancer Survivorship Care in a National Cancer Institute-Designated Comprehensive Cancer Center
Kenneth Miller, Rutika Mehta, Joseph Abraham, et al.
The Oncologist
|
December 3, 2025
A phase II study of trifluridine/tipiracil in combination with ramucirumab in advanced, refractory gastric, or gastroesophageal junction adenocarcinomas
Dae Won Kim, Richard D Kim, Maria Martinez Jimenez, et al.
Cancer Biology & Therapy
|
July 7, 2010
ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer
Hitesh Appaiah, Poornima Bhat-Nakshatri, Rutika Mehta, et al.
Journal of Cell Science
|
August 3, 2011
PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer
Emmanuel O Johnson, Kuei-Hua Chang, Yolanda de Pablo, et al.
CA: a Cancer Journal for Clinicians
|
October 18, 2023
Locally advanced mismatch repair-deficient gastroesophageal junction cancer: Diagnosis, treatment modifications, and monitoring
Rutika Mehta, Andrew Sinnamon, Aamir Dam, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 59) with videos related to
Sort By:
Page
of 6
American Journal of Clinical Oncology
|
January 31, 2015
Cancer Survivorship and Models of Survivorship Care: A Review
Kenneth D Miller, Manjari Pandey, Rohit Jain, et al.
Current Oncology (Toronto, Ont.)
|
February 24, 2023
Real-World Molecular Biomarker Testing Patterns and Results for Advanced Gastroesophageal Cancers in the United States
Rutika Mehta, Astra M Liepa, Shen Zheng, et al.
Expert Opinion on Investigational Drugs
|
March 4, 2021
Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies
Rutika Mehta, Anthony C Wood, James Yu, et al.
Journal of Clinical Pathology
|
August 13, 2010
Expression of high-molecular-weight cytokeratin (34betaE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast
Rutika Mehta, Rohit K Jain, Nour Sneige, et al.
Oncology Reports
|
September 30, 2010
Loss of ERα and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model
Kasi McCune, Rutika Mehta, Mangesh A Thorat, et al.
American Journal of Clinical Oncology
|
September 12, 2015
Patterns of Long-term Cancer Survivorship Care in a National Cancer Institute-Designated Comprehensive Cancer Center
Kenneth Miller, Rutika Mehta, Joseph Abraham, et al.
The Oncologist
|
December 3, 2025
A phase II study of trifluridine/tipiracil in combination with ramucirumab in advanced, refractory gastric, or gastroesophageal junction adenocarcinomas
Dae Won Kim, Richard D Kim, Maria Martinez Jimenez, et al.
Cancer Biology & Therapy
|
July 7, 2010
ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer
Hitesh Appaiah, Poornima Bhat-Nakshatri, Rutika Mehta, et al.
Journal of Cell Science
|
August 3, 2011
PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer
Emmanuel O Johnson, Kuei-Hua Chang, Yolanda de Pablo, et al.
CA: a Cancer Journal for Clinicians
|
October 18, 2023
Locally advanced mismatch repair-deficient gastroesophageal junction cancer: Diagnosis, treatment modifications, and monitoring
Rutika Mehta, Andrew Sinnamon, Aamir Dam, et al.
Page
of 6